Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Smarter. Stronger. Together: Achieving Quality HER2-Positive Breast Cancer Care by Educating Providers and Patients
  • CME
  • CE

Credits Available
Physicians: maximum of 1.5 AMA PRA Category 1 Credits
Registered Nurses: 1.5 Nursing contact hours
Pharmacists: 1.5 contact hours (0.15 CEUs)
Released: April 28, 2022 Expiration: April 27, 2023
Start Activity
Provided by Clinical Care Options, LLC in partnership with Smart Patients.

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

 
Supported by educational grants from
AstraZeneca
Daiichi Sankyo, Inc.
Puma Biotechnology, Inc.
Seagen Inc.
Sara Hurvitz, MD, FACP
Program Director
Aditya Bardia, MD, MPH
Kristi Kay Orbaugh, MSN, NP, AOCNP
Danielle Roman, PharmD, BCOP

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Address gaps in patient–provider knowledge and perceptions about current and emerging treatment options for HER2-positive breast cancer
  • Foster collaborative discussions between patients/caregivers and providers on guidelines and recent clinical evidence to guide personalized treatment planning for HER2-positive breast cancer
  • Implement resources to engage patients in shared decision-making about treatment for HER2-positive breast cancer

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Program Director

Sara Hurvitz, MD, FACP

Professor of Medicine
Director,
Breast Oncology Program
Division of Hematology-Oncology
Department of Medicine
David Geffen School of Medicine at UCLA
Los Angeles, California

Sara Hurvitz, MD, FACP, has disclosed that she has received funds for research support from Ambrx, Amgen, Arvinas, AstraZeneca, Bayer, CytomX, Daiichi-Sankyo, Dignitana, Genentech/Roche, Gilead Sciences, GlaxoSmithKline, Immunomedics, Lilly, MacroGenics, Novartis, OBI Pharma, Orinove, Pfizer, Phoenix Molecular Designs, Pieris, PUMA, Radius, Sanofi, Seattle Genetics/Seagen, and Zymeworks.

Faculty

Aditya Bardia, MD, MPH

Director, Breast Cancer Research
Associate Professor
Harvard Medical School
Attending Physician
Massachusetts General Hospital
Boston, Massachusetts

Aditya Bardia, MD, MPH, has disclosed that he has received consultant/advisor/speaker fees from AstraZeneca, Daiichi Pharma, Foundation Medicine, Genentech, Gilead Sciences, Immunomedics, Lilly, Merck, Novartis, Pfizer, Phillips, Radius Health, and Sanofi and funds for research support from AstraZeneca, Daiichi Pharma, Genentech, Gilead Sciences, Immunomedics, Lilly, Merck, Novartis, Pfizer, Radius Health, and Sanofi.
Kristi Kay Orbaugh, MSN, NP, AOCNP

Adult Oncology Nurse Practitioner
Community Hospital Oncology Physicians
Indianapolis, Indiana

Kristi Kay Orbaugh, MSN, NP, AOCNP, has disclosed that she has been a speaker for AstraZeneca, Bristol-Myers Squibb, DSI, Gilead Sciences, Lilly, Morphosys, Pfizer, Regeneron, and Sanofi.
Danielle Roman, PharmD, BCOP

Manager, Clinical Pharmacy Services
Allegheny Health Network
Pittsburgh, Pennsylvania

Danielle Roman, PharmD, BCOP, has no relevant conflicts of interest to report.

Staff

Kristen Rosenthal, PhD

Senior Scientific Director

Kristen Rosenthal, PhD, has no relevant conflicts of interest to report.
Kelly Brandt, PharmD
Kelly G. Brandt, PharmD, BCOP, BCPS, has no relevant conflicts of interest to report.
Gordon Kelley

Senior Clinical Editor

Gordon Kelley has no relevant conflicts of interest to report.
Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.
June Wasserstrom

Director, CME Program Development

June Wasserstrom has no relevant conflicts of interest to report.
Jim Mortimer

Senior Director, Oncology Programs and Partnership Development

Jim Mortimer has disclosed he had individually publicly traded stocks/stock options in AstraZeneca.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This educational program is intended for oncologists, advanced practice clinicians, oncology nurses, navigators, pharmacists, and other supportive services and their patients with HER2-positive breast cancer.

Goal

The goal of this activity is to educate oncologists, oncology nurses, pharmacists, and other healthcare professionals about recent developments in the care of HER2-positive breast cancer to optimally individualize therapy for this patient population.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.5 contact hours.

Continuing Pharmacy Education

Credit Designation

CCO designates this continuing education activity for 1.5 contact hours (0.15 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-22-124-H01-P.

Type of Activity: Application

Upon successfully completing the post-test with a score of 65% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from April 28, 2022, through April 27, 2023:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Smarter. Stronger. Together: Achieving Quality HER2-Positive Breast Cancer Care by Educating Providers and Patients
  • CME
  • CE

Loading...
In this on-demand webcast of a live symposium, expert faculty use case studies to highlight the latest safety and efficacy evidence supporting optimal management of patients with HER2-positive breast cancer.
Sara Hurvitz, MD, FACP
Program Director
Aditya Bardia, MD, MPH
Kristi Kay Orbaugh, MSN, NP, AOCNP
Danielle Roman, PharmD, BCOP
Physicians: maximum of 1.5 AMA PRA Category 1 Credits
Registered Nurses: 1.5 Nursing contact hours
Pharmacists: 1.5 contact hours (0.15 CEUs)
Released: April 28, 2022 Expiration: April 27, 2023

Related Content

Commentary from Nelson F. Sanchez, MD, on caring for transgender individuals, from the healthcare disparities they face to how healthcare professionals can improve their care, from Clinical Care Options (CCO)

Nelson F. Sanchez, MD
Program Director
Released: June 28, 2022

Results from LUMINA trial showing very low local recurrence rate with omission of radiotherapy after breast-conserving surgery in patients with low-risk luminal A breast cancer, presented at ASCO 2022 and reported by Clinical Care Options (CCO)

Released: June 15, 2022

Exploratory analysis of EFS by residual cancer burden from KEYNOTE-522 evaluating neoadj pembrolizumab plus chemotherapy followed by adj pembrolizumab for early-stage TNBC, presented at ASCO 2022 and reported by Clinical Care Options (CCO)

Released: June 14, 2022

PALOMA-2 study: final OS analysis with palbociclib plus letrozole in ER-positive/HER2-negative advanced breast cancer, presented at ASCO 2022 and reported by Clinical Care Options (CCO)

Released: June 10, 2022
Provided by Clinical Care Options, LLC in partnership with Smart Patients.

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

 
Supported by educational grants from
AstraZeneca
Daiichi Sankyo, Inc.
Puma Biotechnology, Inc.
Seagen Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings